Risk factors
Jasper Therapeutics (JSPR) risk factors
Item 1A of every Jasper Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors68 risks5 new2 dropped11 reworded
Jasper Therapeutics faces severe going concern doubts, relying heavily on briquilimab development while restructuring operations.
Filed Mar 30, 2026 - FY2024 10-K risk factors65 risks
Jasper Therapeutics faces substantial doubt about its going concern status due to recurring net losses and negative operating cash flows. The company is heavily dependent on the clinical success, regulatory approval, and commercialization of its lead product candidate, briquilimab. Operations rely significantly on third-party intellectual property licenses and securing substantial additional financing.
Filed Feb 28, 2025